A number of studies presented at the Alzheimer’s Association International Conference, showed that regular supervised exercise sessions could help to improve symptoms in people with memory problems and dementia
Results of a phase 3 trial of Alzheimer’s drug solanezumab are to be presented today (22 July) at the Alzheimer’s Association International Conference 2015.
Researchers from across the world are gathering in Washington DC for the Alzheimer’s Association International Conference 2015. Today saw announcements from clinical trials with potential new Alzheimer’s treatments.
Clinical trial results for two potential symptomatic Alzheimer’s treatments suggest that the drugs may be able to improve memory and thinking, or symptoms of agitation and aggression.
Researchers in Cambridge are embarking on a pilot trial to investigate the potential of the hormone oxytocin to combat early symptoms of frontotemporal dementia (FTD), backed by a grant from Alzheimer’s Research UK.
It has been reported today that a drug commonly used to treat type 2 diabetes is to be tested in a clinical trial for Alzheimer’s disease. The drug, liraglutide, is to be evaluated in a phase 2 trial of people in the early stages of Alzheimer’s at centres across the UK
Early results from a phase 1b trial of a new Alzheimer’s drug suggest possible benefits for people in the early stages of the disease. The antibody, known as aducanumab or BIIB037, was tested by pharmaceutical company Biogen, with results presented today at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders in Nice, France.
A review of existing evidence suggests that computer ‘brain training’ programmes may have some small benefits for older people, but that more evidence is required to know how long these benefits might last.
A small clinical trial has shown that in older people, a diet supplemented with cocoa flavanols– naturally occurring compounds found in cocoa beans – may help blood flow in a brain region important for memory.
Reports in the news today highlight a new scheme aimed at increasing the number of people with dementia who have a diagnosis.